Combination therapy for BRAF-mutated colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have metastatic colorectal cancer with a specific genetic mutation called BRAF V600E.
- Your tumor must be microsatellite stable (MSS), meaning it does not have another specific genetic feature.
- You must have had 1 or 2 prior treatments for metastatic cancer that have stopped working.
- You must be in generally good health, with a performance status of 0 or 1 (able to carry out daily activities).
- Your heart, liver, kidney, and blood cell counts must be within certain acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the targeted therapy combination encorafenib (a BRAF inhibitor) plus cetuximab (an anti-EGFR antibody) again can help people whose metastatic colorectal cancer has a BRAF V600E mutation and whose disease progressed after a prior response to a similar treatment.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
This trial tests a combination of targeted therapy (dabrafenib) and two other drugs (cetuximab or panitumumab) plus standard chemotherapy (FOLFOX) as a first treatment for people with a specific type of metastatic colorectal cancer that has a BRAF V600E mutation and is microsatellite stable.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.